US 11,433,055 B2 · Chromane monobactam compounds for the treatment of bacterial infections

Abstract

The present invention relates to monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof. The present invention also relates to compositions which comprise a monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

A compound of Formula I

or a pharmaceutically acceptable salt thereof, wherein:
T, U and V are each CH;
W is O;
Q is CR3;
X is CH2;
Y is O or CH2,
Z is O or CHn,
A is
1) —C(═NH)—NH,
2) AryC, or
3) HetC,
wherein A is unsubstituted or substituted with one to four Ri;
AryC is a 5- to 6-membered monocyclic aromatic ring with 0, 1, 2, or 3 ring atoms independently selected from N, N as a quaternary salt, O and S, unsubstituted or substituted with one to four Ri, wherein AryC is optionally fused to a 4- to 7-membered heterocycloalkyl ring containing one to two heteroatoms selected from O, S and —NRg;
HetC is a 4- to 7-membered saturated or monounsaturated monocyclic ring with 1, 2, or 3 heteroatom ring atoms independently selected from N, N as a quaternary salt, O and S, unsubstituted or substituted with one to four Ri;
L is
1) absent,
2) R4,
3) —NHR4,
4) —N(R4)2,
5) —OR4,
6) —(CH2)nR4,
7) —C(O)R4,
8) —C(NH)R4, or
9) —S(O)mR4,
wherein L is unsubstituted or substituted with 1-4 substituents selected from Re;
M is
1) R5,
2) —NHR5,
3) —N(R5)2,
4) —OR5,
5) —(CH2)uR5,
6) —C(O)R5,
7) —C(NH)R5, or
8) —S(O)vR5,
wherein M is unsubstituted or substituted with 1-4 substituents selected from R6;
R1 and R2 are independently selected from:
1) hydrogen,
2) —C1-C8 alkyl, and
3) —C(O)ORe,
wherein —C1-C8 alkyl is unsubstituted or substituted with one to three Ra,
provided that if R1 is —C(O)ORe, then R2 is not —C(O)ORe,
R3 is hydrogen;
each occurrence of R4 is independently:
1) hydrogen,
2) —C1-C10 alkyl,
3) —C2-C8 alkenyl,
4) —(CH2)nORe,
5) —S(O)mRe,
6) —S(O)mNRcRd,
7) —(CH2)nNRcRd,
8) —OC(O)Re,
9) —C(O)ORe,
10) —CN,
11) —C(O)NRcRd,
12) —NRc(O)Re,
13) —NRcC(O)ORe,
14) —NRc(O)NRcRd,
15) —NRcS(O)mRe,
16) ═NR11,
17) —C3-C7 cycloalkyl,
18) —O—C3-C6cycloalkyl,
19) —C1-C10alkylene-C3-C6cycloalkyl,
20) —O—C1-C10alkylene-C3-C6cycloalkyl,
21) HetB,
22) —O-HetB,
23) —C1-C10alkylene-HetB,
24) —O—C1-C10alkylene-HetB,
25) AryB,
26) —O-AryB,
27) —C1-C10alkylene-AryB, or
28) —O—C1-C10alkylene-AryB,
wherein R4 is unsubstituted or substituted with one to four R6;
AryB is a 5- to 6-membered monocyclic aromatic ring with 0, 1, 2, or 3 ring atoms independently selected from N, O and S, unsubstituted or substituted with one to four W;
HetB is a 4- to 7-membered saturated or monounsaturated monocyclic ring with 1, 2, or 3 heteroatom ring atoms independently selected from N, N as a quaternary salt, O and S, unsubstituted or substituted with one to three Ra;
R5 is
1) hydrogen,
2) C1-C10 alkyl,
3) —C2-C8 alkenyl,
4) —(CH2)uORe,
5) —S(O)vRe,
6) —S(O)vNRcRd,
7) —(CH2)uNRcRd,
8) —OC(O)Re,
9) —C(O)ORe,
10) —CN,
11) —C(O)NReRd,
12) —NRcC(O)Re,
13) —NRcC(O)ORe,
14) —NRcC(O)NRcRd,
15) —NRcS(O)vRe,
16) ═NR11,
17) —C3-C7 cycloalkyl,
18) —O—C3-C6cycloalkyl,
19) —C1-C10alkylene-C3-C6cycloalkyl,
20) —O—C1-C10 alkylene-C3-C6cycloalkyl,
21) HetB,
22) —O-HetB,
23) —C1-C10alkylene-HetB,
24) —O—C1-C10 alkylene-HetB,
25) AryB,
26) —O-AryB,
27) —C1-C10alkylene-AryB, or
28) —O—C1-C10alkylene-AryB,
wherein R5 is unsubstituted or substituted with one to four R6;
each occurrence of R6 is independently:
1) halogen,
2) —C1-C6alkyl,
3) —ORe,
4) —S(O)vRe,
5) —S(O)vNRcRd,
6) —C(O)Re,
7) —OC(O)Re,
8) —C(O)ORe,
9) —CN,
10) —C(O)NRcRd,
11) —C(NH)NRcRd,
12) —(CH2)uNRcRd,
13) —(CH2)uNRcRd,
14) —N(Rc)(C(O)Re),
15) —N(Rc)(C(O)ORe),
16) —N(Rc)(C(O)NRcRd),
17) —N(Rc)(S(O)vRe), or
18) HetB;
R7 is
1) hydrogen,
2) C1-C3 alkyl, or
3) C3-C7 cycloalkyl,
wherein C1-C3 alkyl and C3-C7 cycloalkyl are unsubstituted or substituted with one to three Ra;
R8 is
1) hydrogen,
2) C1-C4 alkyl, or
3) C3-C7 cycloalkyl;
R9 is
1) hydrogen,
2) C1-C4 alkyl, or
3) C3-C7 cycloalkyl;
R10 is
1) hydrogen,
2) C1-C4 alkyl, or
3) C3-C7 cycloalkyl;
R11 is
1) hydrogen,
2) C1-C4 alkyl, or
3) C3-C7 cycloalkyl;
R12 and R13 are independently C1-C3 alkyl, wherein C1-C3 alkyl is unsubstituted or substituted with one to seven fluorines,
or alternatively R12 and R13 together with the carbon to which they are attached form a monocyclic C4-C6 cycloalkyl unsubstituted or substituted with one to three substituents independently selected from —F, —OH and —OC1-C3alkyl;
each occurrence of Ra is independently:
1) hydrogen,
2) halogen,
3) C1-C3alkyl,
4) —NRcRd, or
5) —ORe;
each occurrence of Rb is independently:
1) hydrogen,
2) —C1-C6 alkyl,
3) —OC1-C6 alkyl,
4) OH,
5) N(R9)2, or
6) halogen,
wherein —C1-C3 alkyl is unsubstituted or substituted with one to three Ra;
Rc and Rd are independently selected from:
1) hydrogen,
2) —C1-C10 alkyl, and
3) —C2-C10 alkenyl,
wherein each Rc and Rd is unsubstituted or substituted with one to three Rf;
each occurrence of Re is independently hydrogen, or —C1-C10alkyl, wherein each Re is unsubstituted or substituted with one to three Rh;
each occurrence of Rf is independently:
1) halogen,
2) —C1-C10 alkyl,
3) —OH,
4) —OC1-C4 alkyl,
5) —S(O)mC1-C4 alkyl,
6) —CN,
7) —CF3,
8) —OCHF2,
9) —OCF3, or
10) NH2,
wherein —C1-C10 alkyl is unsubstituted or substituted with one to three substituents independently
selected from —OH, halogen, cyano, and —S(O)2CH3;
each occurrence of Rg is independently:
1) hydrogen,
2) —C(O)Re, or
3) —C1-C10 alkyl,
wherein —C1-C10alkyl is unsubstituted or substituted with one to five fluorines;
each occurrence of Rh is independently:
1) halogen,
2) —C1-C10alkyl,
3) —OH,
4) —OC1-C4 alkyl,
5) —S(O)mC1-C4 alkyl,
6) —CN,
7) —CF3,
8) —OCHF2, or
9) —OCF3,
wherein —C1-C10 alkyl is unsubstituted or substituted with one to three substituents independently selected from:
—OH, halogen, cyano, or —S(O)2CH3;
each occurrence of Ri is independently:
1) —C1-C8 alkyl,
2) —C2-C8 alkenyl,
3) —C2-C8 alkynyl,
4) halogen,
5) —ORe,
6) —S(O)mRe,
7) —S(O)mNRcRd,
8) —C(O)Re,
9) —OC(O)Re,
10) —C(O)ORe,
11) —CN,
12) —C(O)NRcRd,
13) —NRcRd,
14) —(CH2)nNRcRd,
15) —NRcC(O)Re,
16) —NRcC(O)ORe,
17) —NRcC(O)NRcRd,
18) —NRcS(O)mRe,
19) ═NH,
20) —CF3,
21) —OCF3, or
22) —OCHF2;
each occurrence of Rj is independently:
1) hydrogen,
2) C1-C3 alkyl,
3) OR10,
4) ═NR10,
5) N(R10)2, or
6) halogen,
wherein C1-C3 alkyl unsubstituted or substituted with one to three Rb;
each n is independently 0, 1, 2, 3, 4, 5 or 6;
each m is independently 0, 1 or 2;
each p is independently 1 or 2;
each q is independently 0, 1, 2, 3, 4, 5 or 6;
each s is independently 0, 1, 2 or 3;
each t is independently 0, 1, 2 or 3;
each u is independently 0, 1, 2, 3, 4, 5 or 6;
and
each v is independently 0, 1, or 2.

233 more elements

Chromane monobactam compounds for the treatment of bacterial infections

Life of this patent

Chromane monobactam compounds for the treatment of bacterial infections

Life of this patent

Abstract

Claims21